The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
Researchers used fine mapping and other approaches to prioritize proposed coding and non-coding causal variants at rheumatoid arthritis- and type 1 diabetes-linked loci.
These differentially variable positions appear to implicate stress response in rheumatoid arthritis development and possibly in other autoimmune conditions.
The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
The partners are initially planning to make searchable whole-genome data and EMRs from more than 1,000 rheumatoid arthritis patients accessible to trial developers.
